Market OpportunityDynavax anticipates that the expanded market opportunity for vaccination against Hepatitis-B in the U.S. could grow to $900M by 2030, with Heplisav-B achieving at least 60% total market share.
Pipeline DevelopmentsPositive developments from the company’s pipeline support potential for further upside.
Share Repurchase ProgramDynavax announced a $200M share repurchase program, with a $100M accelerated share repurchase transaction already completed.